| TaiwanJ Pharmaceuticals makes its debut at 2014 BIO International Convention |
TaiwanJ Pharmaceuticals joined forces with the representatives from Taiwanese R&D Institutions, government agencies, and private biotech companies to showcase their latest innovations and drug development activities at the 2014 BIO International Convention in San Diego, USA.
It was the first time for TaiwanJ Pharmaceuticals to take part in a public international forum of biotechnology drug innovation and development since its founding in 2011. The four drugs in active development in TaiwanJ Pharmaceutical’s product pipeline were introduced for the first time to the international biotechnology community. CEO Dr. Ying-Chu Shih stated that TaiwanJ Pharmaceuticals took this opportunity to explore potential drug development collaborations and alliances with other companies and to seek potential capital investment.
The drug development portfolio of TaiwanJ Pharmaceuticals was discussed with attendees as consisting of 2 re-purposed drugs and 2 new chemical entities (regulatory). Its therapeutic areas of focus were presented as chronic liver diseases, including liver inflammation, liver fibrosis, NASH and NALFD, and autoimmune diseases, such as rheumatoid arthritis and Crohn’s Disease.
TaiwanJ Pharmaceuticals anticipates floating an IPO in about two years in Taiwan.
Interest in TaiwanJ Pharmaceuticals can be addressed to its Project Manager, Ms. Yi-Ting Tsai [email: yttsai@taiwanj.com].
It was the first time for TaiwanJ Pharmaceuticals to take part in a public international forum of biotechnology drug innovation and development since its founding in 2011. The four drugs in active development in TaiwanJ Pharmaceutical’s product pipeline were introduced for the first time to the international biotechnology community. CEO Dr. Ying-Chu Shih stated that TaiwanJ Pharmaceuticals took this opportunity to explore potential drug development collaborations and alliances with other companies and to seek potential capital investment.
The drug development portfolio of TaiwanJ Pharmaceuticals was discussed with attendees as consisting of 2 re-purposed drugs and 2 new chemical entities (regulatory). Its therapeutic areas of focus were presented as chronic liver diseases, including liver inflammation, liver fibrosis, NASH and NALFD, and autoimmune diseases, such as rheumatoid arthritis and Crohn’s Disease.
TaiwanJ Pharmaceuticals anticipates floating an IPO in about two years in Taiwan.
Interest in TaiwanJ Pharmaceuticals can be addressed to its Project Manager, Ms. Yi-Ting Tsai [email: yttsai@taiwanj.com].